PIQUR Therapeutics AG strengthens its Management Team

PIQUR announces today that Peter Oprandi, former Global CFO Finance Biologics Supply and Operations at AstraZeneca in Gaithersburg, USA, has been appointed Chief Financial Officer. He will report to Dr. Melanie Rolli, CEO, and will join the Executive Management Team with immediate effect. Peter Oprandi succeeds Martin Gasser who will be leaving PIQUR by the end of October 2019. Richard Laube, Chairman PIQUR, said: “we would like to thank Martin for his many achievements at PIQUR over the last two years and we wish him all the best.”

Regarding his appointment, Peter Oprandi said: “Following 20 years of US experience, I’m excited to join PIQUR’s diverse and international team and contribute to the continued success of the organization taking into consideration all of our stakeholders’ interests.” Peter has over 20 years of global finance experience within the life science industry. Prior to AstraZeneca, he spent 17 years at Lonza, where he held positions of increasing responsibility in Auditing, Supply Chain and Finance, and finally served as Senior Vice President/Divisional CFO Lonza Pharma/Biotech. Peter Oprandi has a dual Swiss/US citizenship.

Furthermore, PIQUR informs that Dr. Henk Streefkerk has been promoted to Chief Medical Officer with immediate effect. In his previous role as Multi-Program Medical Director and Drug Safety Officer he was instrumental in advancing PIQUR’s clinical development program, in particular, PIQUR’s innovative topical program. He joined PIQUR from Novartis, first in early clinical development (Translational Medicine, NIBR, Basel), and later in full development (Global Patient Safety, GDD, Basel). His expertise in designing, executing, and reporting early clinical trials, as well as his experience with data-driven benefit-risk evaluations in late-phase clinical development, supported bringing key projects to marketing approval globally. Prior to joining Novartis, Henk worked as a clinical pharmacologist at Actelion and Organon (now Merck), and as a medical doctor at the University Medical Center in Nijmegen, the Netherlands. “I’m highly motivated to bring new therapies to patients with oncologic or dermatologic diseases. Thanks to our team’s agility, we can swiftly respond to demands whilst maintaining a high quality of our clinical programs,” said Henk Streefkerk.

Melanie Rolli, CEO PIQUR, said: “with the recent external hire and the internal promotion, I am confident that PIQUR has an excellent management team in place to execute the organization’s strategic objectives and to further grow the business.” 


Founded in 2011 as a spin-off of the University of Basel, Switzerland, PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancer and genetic diseases. PIQUR’s lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR is a privately owned company that is backed by private investors and Versant Venture, a leading venture capital firm that specializes in investments in innovative biopharmaceuticals. 

Download Press Release PDF


Melanie Rolli, CEO